Immunological outcomes of new tuberculosis vaccine trials: WHO panel 
recommendations

Hanekom, Willem A.; Dockrell, Hazel M.; Ottenhoff, Tom H. M.; Doherty, T. Mark; Fletcher, Helen; McShane, Helen; Weichold, Frank F.; Hoft, Dan F.; Parida, Shreemanta K.; Fruth, Uli J.

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations

MPS-Authors

/persons/resource/persons82090

Parida, Shreemanta K.
Department of Immunology, Max Planck Institute for Infection Biology, Max Planck Society;

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

PLoS_Med_2008_5_e145_1033.pdf
(出版社版), 2MB

付随資料 (公開)

There is no public supplementary material available

引用

Hanekom, W. A., Dockrell, H. M., Ottenhoff, T. H. M., Doherty, T. M., Fletcher, H., McShane, H., Weichold, F. F., Hoft, D. F., Parida, S. K., & Fruth, U. J. (2008). Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Medicine, 5(7):, pp. 1033-1036.

引用: https://hdl.handle.net/11858/00-001M-0000-000E-C1AE-7

要旨

Summary Points * Many new and diverse tuberculosis vaccines are currently under development. * The ability to compare clinical immunogenicity between different candidates would be an important asset. * The World Health Organization (WHO) Initiative for Vaccine Research sponsored three meetings of experts to discuss assay harmonization for new tuberculosis vaccine trials. * We describe advantages and disadvantages of multiple T cell assay approaches and make specific recommendations for phase I/IIa trials. These include introducing a single and simple harmonised assay for all trials.